Published Paper Details:

Background: The purpose of this systematic review is to evaluate published literature on the risk of CQ or HCQ treatment in people with epilepsy. In the COVID-19 pandemic, treatment is required against the SARS CoV-2 virus. CQ or HCQ are the proposed drugs that attract the attention of the public. However, the packaging indicates that these medications can relieve patients with epilepsy, and as a result, there are growing concerns in the epilepsy community. Methods: PubMed (1970 to March 27, 2020) and Embase (1970 to March 27, 2020) were CQ or HCQ names and searched for numbness or convulsions. Selected studies were reviewed and drug reactions were bad. Results: Of the 31 studies, only 11 were considered in favor of systematic analysis. With CQ, subjects are worth a prospective case study (n = 109), two case series (n = 6) and six issue reports. After taking 1000 mg, excluding an epileptic patient, the efficacy of CQ varies between 100-500 mg per day. For HCQ, there is a case study (n = 631) and a case report. Clinical trials have failed to identify any significant association between seizures and CQ or HCQ. Conclusions: Despite the increased risk of seizures from packaging, a systematic review highlights that Class 1 evidence does not support such statements. Therefore, practitioners should understand that information on this particular topic is limited to most cases and case reports. . There is little evidence to suggest that these drugs increase the risk of epilepsy.